- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00390325
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma
Study Overview
Status
Conditions
- Multiple Endocrine Neoplasia Type 2A
- Multiple Endocrine Neoplasia Type 2B
- Recurrent Thyroid Gland Medullary Carcinoma
- Hereditary Thyroid Gland Medullary Carcinoma
- Locally Advanced Thyroid Gland Medullary Carcinoma
- Sporadic Thyroid Gland Medullary Carcinoma
- Stage III Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IV Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To assess objective response rate of sorafenib tosylate (sorafenib [BAY 43-9006]) in metastatic medullary thyroid carcinoma in setting of inherited tumor syndromes, such as multiple endocrine neoplasia (MEN) 2A, MEN 2B, or familial medullary thyroid carcinoma (FMTC).
II. To assess objective response rate of sorafenib (BAY 43-9006) in sporadic metastatic medullary thyroid carcinoma.
SECONDARY OBJECTIVES:
I. To assess toxicity of sorafenib (BAY 43-9006) in patients with metastatic medullary thyroid carcinoma.
II. Measure serum tumor markers calcitonin and carcinoembryonic antigen (CEA) pre-, during, and post-treatment to correlate with disease response.
III. Correlate nuclear medicine functional imaging (fludeoxyglucose F 18 [F-18 fluorodeoxyglucose] positron emission tomography [PET] scan) data obtained at pre-, during, and post-treatment with tumor response.
IV. Correlate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data obtained at pre-, during, and post-treatment with changes in tumor permeability and vascularity with tumor response.
V. Perform pharmacogenomic studies on procured peripheral blood mononuclear cells (PBMCs) if clinical responses are observed.
VI. To correlate between the degree of retrovirus-associated sequence (Ras)-mitogen-activated protein kinase (MAPK) signaling inhibition and vascular endothelial growth factor (VEGF) expression in the tumor and clinical response.
VII. To correlate between the presence and type of ret proto-oncogene (RET) gene defects in tumor and clinical response.
OUTLINE:
Patients receive sorafenib tosylate orally (PO) twice daily (BID) in the absence of disease progression or unacceptable toxicity.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ELIGIBILITY CRITERIA SPECIFIC FOR ARM A
- Histologically confirmed medullary thyroid carcinoma under the clinical setting of inherited tumor syndromes, such as multiple endocrine neoplasia (MEN) 2A, MEN 2B, or familial medullary thyroid carcinoma (FMTC)
- ELIGIBILITY CRITERIA SPECIFIC FOR ARM B
- Histologically confirmed medullary thyroid carcinoma under the clinical setting of sporadic medullary thyroid carcinoma (MTC)
- ELIGIBILITY CRITERIA COMMON FOR ARMS A AND B
- Patients must have measurable disease
- Metastatic and/or locally advanced or locally recurrent disease
- Oral or intravenous (IV) bisphosphonates therapy will be allowed for patients with bony metastasis at the investigator's discretion; bisphosphonate usage should be recorded if used since these agents may have anti-farnesyl transferase activity and may have some therapeutic effect in combination with sorafenib
- Life expectancy must be >= six months
- Patients must have an Eastern Cooperative Oncology Group performance status 0-2
- Leukocytes >= 2,000/uL (10 days prior to patient enrollment)
- Absolute neutrophil count >= 1,000/uL (10 days prior to patient enrollment)
- Platelets >= 100,000/uL (10 days prior to patient enrollment)
- Total bilirubin =< within 2 x upper limit of normal (10 days prior to patient enrollment)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< within 3 x upper limit of normal (10 days prior to patient enrollment)
- Serum creatinine within normal institutional limits OR creatinine clearance > 30 mL/min (by Cockcroft-Gault formula) (10 days prior to patient enrollment)
- The effects of sorafenib (BAY 43-9006) on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because kinase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 30 days after completion of therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- EXCLUSION CRITERIA FOR ARM A AND B
- Patients who have had systemic anti-tumor therapy (such as chemotherapy, biologic modifiers or antiangiogenic therapy) within 4 weeks (6 weeks if nitrosourea or mitomycin chemotherapy) prior to study entry
- Patients who have had external beam radiation therapy within 1 week or if the adverse events associated with radiation are not resolved to grade 1 or less prior to study entry
- Prior therapy with sorafenib (BAY 43-9006), ZD 6474 or AMG-706
- Patients currently receiving any other tumor-specific therapy for thyroid cancer or investigational therapy; patients receiving adjuvant hormonal therapy for a second primary (such as breast cancer or prostate cancer) are allowed to participate as far as there are no known drug interactions
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib (BAY 43-9006)
- Patients unable to swallow sorafenib tablets (e.g. any condition that impairs patient's ability to swallow pills)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with any evidence of a bleeding diathesis
- Patients actively receiving anticoagulation with therapeutic intent; prophylactic anticoagulation (i.e. low dose warfarin) or venous or arterial access devices is allowed provided that the prothrombin time (PT), international normalized ratio (INR) or partial thromboplastin time (PTT) are normal
- Pregnant women or women who are breast-feeding are excluded from this study because sorafenib (BAY 43-9006) is an investigational agent and teratogenicity has not been evaluated yet; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sorafenib (BAY 43-9006), breastfeeding should be discontinued if the mother is treated with sorafenib (BAY 43-9006)
- Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with sorafenib (BAY 43-9006); patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy
- Patients taking the cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, or phenobarbital), rifampin or St. John's wort due to potential drug interactions with sorafenib
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (sorafenib tosylate)
Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic Medullary Thyroid Cancer
Time Frame: Up to 4 weeks after last dose of sorafenib tosylate
|
Measured using MRI scans.
Determined using Response Evaluation Criteria in Solid Tumors/World Health Organization response criteria.
95% confidence interval will be calculated to estimate the frequency of response.
|
Up to 4 weeks after last dose of sorafenib tosylate
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Decreased Calcitonin Levels
Time Frame: Up to 4 weeks after last dose of sorafenib tosylate
|
Identifying the number of patients with decreased calcitonin levels
|
Up to 4 weeks after last dose of sorafenib tosylate
|
Patient With Decreased Carcinoembryonic Antigen (CEA) Levels
Time Frame: Up to 4 weeks after last dose of sorafenib tosylate
|
Identify the number of patients with decreased Carcinoembryonic Antigen (CEA) levels
|
Up to 4 weeks after last dose of sorafenib tosylate
|
Percent of Baseline Dynamic-Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Exchange Rate Constant (Kep)
Time Frame: Up to 4 weeks after last dose of sorafenib tosylate
|
Median decrease in exchange rate Kep in index lesions
|
Up to 4 weeks after last dose of sorafenib tosylate
|
Degree of Ras-MAPK Signaling Inhibition in the Tumor
Time Frame: Up to 4 weeks after last dose of sorafenib tosylate
|
Identify the number of patients with degree of Ras-MAPK signaling inhibition
|
Up to 4 weeks after last dose of sorafenib tosylate
|
Degree of Vascular Endothelial Growth Factor (VEGF) Expression in the Tumor
Time Frame: Up to 4 weeks after last dose of sorafenib tosylate
|
Correlated with clinical response.
|
Up to 4 weeks after last dose of sorafenib tosylate
|
Standardized Uptake Value (SUV Max) as Measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET)
Time Frame: Up to 4 weeks after last dose of sorafenib tosylate
|
Identify the median SUV at baseline and 8 week follow up as measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET).
|
Up to 4 weeks after last dose of sorafenib tosylate
|
Number of Patients With Toxicity, Graded Using the Revised National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0
Time Frame: Up to 4 weeks after last dose of sorafenib tosylate
|
Toxicities were graded for patients using the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
|
Up to 4 weeks after last dose of sorafenib tosylate
|
Number of Participants With Ret Proto-Oncogene (RET) Gene Defects in the Tumor
Time Frame: Baseline
|
Percent of patients with RET mutations
|
Baseline
|
Selected Polymorphisms of Genes Influencing Sorafenib Tosylate Metabolism and/or Resistance Genes That May Predict Response or Toxicity
Time Frame: Baseline
|
Changes will be correlated with toxicity and clinical response to therapy.
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bhavana Konda, Ohio State University Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Genetic Diseases, Inborn
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplastic Syndromes, Hereditary
- Neuroendocrine Tumors
- Neoplasms, Multiple Primary
- Neoplasms, Ductal, Lobular, and Medullary
- Neoplasms
- Carcinoma
- Thyroid Diseases
- Thyroid Neoplasms
- Carcinoma, Neuroendocrine
- Endocrine Gland Neoplasms
- Multiple Endocrine Neoplasia
- Carcinoma, Medullary
- Multiple Endocrine Neoplasia Type 2a
- Multiple Endocrine Neoplasia Type 2b
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Sorafenib
Other Study ID Numbers
- NCI-2009-00196 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P30CA016058 (U.S. NIH Grant/Contract)
- N01CM62207 (U.S. NIH Grant/Contract)
- N01CM00070 (U.S. NIH Grant/Contract)
- 2006C0050
- NCI-7609
- CDR0000507441
- OSU 06054 / IRB 2006C0050
- 7609 (Other Identifier: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Endocrine Neoplasia Type 2A
-
National Cancer Institute (NCI)CompletedMultiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Medullary Thyroid CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedMultiple Endocrine Neoplasia Type 2 | Medullary Thyroid CarcinomaUnited States
-
Centre Hospitalier Universitaire DijonRecruitingMultiple Endocrine NeoplasiaFrance
-
Centre Hospitalier Universitaire DijonUnknownType 1-Multiple Endocrine Neoplasia SyndromeFrance
-
Centre Hospitalier Universitaire DijonRecruiting
-
National University Health System, SingaporeCompletedThymic Carcinoid | Multiple Endocrine Neoplasia Type 1 (MEN-1)Singapore
-
Genzyme, a Sanofi CompanyCompletedThyroid CancerItaly, Spain, Romania, Netherlands, Canada, United States, Switzerland, Australia
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)WithdrawnMerkel Cell Carcinoma | Neuroendocrine Neoplasm | Metastatic Carcinoid Tumor | Functional Pancreatic Neuroendocrine Tumor | Malignant Somatostatinoma | Metastatic Adrenal Gland Pheochromocytoma | Multiple Endocrine Neoplasia Type 1 | Multiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia... and other conditions
-
University Hospital, Basel, SwitzerlandRecruiting
-
M.D. Anderson Cancer CenterActive, not recruitingMultiple Endocrine Neoplasia SyndromesUnited States
Clinical Trials on Sorafenib Tosylate
-
National Cancer Institute (NCI)Active, not recruitingGastrointestinal Stromal TumorUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic... and other conditionsUnited States
-
National Cancer Institute (NCI)Gynecologic Oncology GroupCompletedRecurrent Ovarian Carcinoma | Primary Peritoneal CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterBayerTerminated
-
Kyowa Hakko Kirin Pharma, Inc.CompletedPeripheral T-Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedJuvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)CompletedAdvanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedHilar Cholangiocarcinoma | Recurrent Gallbladder Carcinoma | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Gallbladder Adenocarcinoma | Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Bile Duct Adenocarcinoma | Gallbladder Adenocarcinoma With Squamous... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedNon-Small-Cell Lung CarcinomaUnited States